No annual revenue total was found in Acurx Pharmaceuticals, Inc.'s SEC filings.
Acurx Pharmaceuticals, Inc. (ACXP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income (TTM)
$-7.51M
+24.9% vs year-ago TTM
Operating cash flow (TTM)
$-6.18M
+24.2% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-2.80
+73.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.86M
-87.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Staten Island, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1736243
- Former names
- Acurx Pharmaceuticals, LLC (until Jun 23, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$8.1M | — | — | — | — |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M |
| Diluted EPS | -$5.32 | -$17.45 | -$1.15 | -$1.12 | -$1.49 |
| Operating cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 |
| Stockholders' equity | $5.3M | $615,121 | $4.7M | $7.3M | — |
| Cash and investments | $7.6M | $3.7M | $7.5M | $9.1M | $13.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 16, 2026 | Oct 16, 2026 |
| ARS | Annual report to shareholders | Sep 1, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Apr 16, 2026 | Apr 15, 2026 |
All 245 Acurx Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.